Centre for Gout and Metabolic Bone and Joint Diseases, Ospedale Civile SS. Giovanni e Paolo, Venezia, Italy.
Laboratory Medicine Unit, Department of Medicine-DIMED, University of Padova, Italy.
Clin Exp Rheumatol. 2024 Jan;42(1):1-9. doi: 10.55563/clinexprheumatol/uhyzcr. Epub 2024 Jan 24.
Gout is a chronic joint disease caused by the deposition of monosodium urate crystals into and around the articular tissues. In the last two years, new insights regarding diagnosis, genetic involvement, pathogenesis, comorbidities, and clinical data, have allowed the identification of new strategies to improve the control of the disease and its flares. In keeping, the discover of new mechanisms concerning crystal-induced inflammation have suggested new ways for the management not only of gout, but also other systemic diseases, mainly including renal and cardiovascular disorders. In this context it is very representative the case of colchicine which, given the surprising results obtained both in laboratory and clinical experiments, has recently received by FDA the approval for the prevention of cardiovascular disorders.
痛风是一种慢性关节疾病，由单钠尿酸盐晶体在关节组织内和周围沉积引起。在过去的两年中，新的见解涉及诊断、遗传参与、发病机制、合并症和临床数据，为改善疾病及其发作的控制提供了新的策略。随之而来的是，新的晶体诱导炎症机制的发现，为痛风以及其他系统性疾病的治疗提供了新的途径，主要包括肾脏和心血管疾病。在这方面，秋水仙碱是一个非常典型的例子，鉴于其在实验室和临床实验中取得的惊人结果，最近已获得 FDA 批准用于预防心血管疾病。
